Orgenics

Company Overview

Snapshot

Founded in January 1982, Orgenics operates with over 500 employees. The company was acquired by Alere in January 1996, marking a significant milestone in its corporate trajectory.

Business overview

Orgenics specializes in developing diagnostic products designed to detect serious and life-threatening conditions and diseases. The company's core technology includes patented ImmunoComb products, which are rapid enzyme immunoassays capable of identifying antibodies or antigens in human serum or plasma. These products are characterized by their speed, ease of use, high sensitivity, and specificity, making them suitable for decentralized clinical laboratories, field hospitals, and remote rural areas. Orgenics serves global markets, contributing to increased awareness and early detection of HIV and other infectious diseases through its product delivery to partners and customers across more than 150 countries.

Strategic signal

In August 2013, the FDA approved the first rapid test for HIV-1/2 antibodies and HIV-1 antigen, a development that signals a significant advancement in diagnostic capabilities for infectious diseases. This regulatory approval underscores the industry's focus on rapid, accessible testing solutions, which aligns with Orgenics' expertise in developing quick and easy-to-use diagnostic products.

Company Intelligence Q&A

When was Orgenics founded?

Orgenics was founded in January 1982.

What is Orgenics' primary focus?

Orgenics focuses on developing accurate and safe diagnostic products for serious and life-threatening conditions and diseases.

What is the key technology offered by Orgenics?

Orgenics offers patented ImmunoComb products, which are rapid enzyme immunoassays for detecting antibodies or antigens in human serum or plasma.

When was Orgenics acquired and by whom?

Orgenics was acquired by Alere in January 1996.

What was a notable regulatory approval related to Orgenics' field?

In August 2013, the FDA approved the first rapid test for HIV-1/2 antibodies and HIV-1 antigen, a significant development in the diagnostic sector.